



The CB₂ receptor and its role as a regulator of inflammation

Caroline Turcotte¹ · Marie-Renée Blanchet¹ · Michel Lavoie¹ · Nicolas Flamand¹

Received: 30 March 2016/Revised: 20 June 2016/Accepted: 27 June 2016/Published online: 11 July 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract The CB₂ receptor is the peripheral receptor for cannabinoids. It is mainly expressed in immune tissues, highlighting the possibility that the endocannabinoid system has an immunomodulatory role. In this respect, the CB₂ receptor was shown to modulate immune cell functions, both in cellulo and in animal models of inflammatory diseases. In this regard, numerous studies have reported that mice lacking the CB₂ receptor have an exacerbated inflammatory phenotype. This suggests that therapeutic strategies aiming at modulating CB₂ signaling could be promising for the treatment of various inflammatory conditions. Herein, we review the pharmacology of the CB₂ receptor, its expression pattern, and the signaling pathways induced by its activation. We next examine the regulation of immune cell functions by the CB₂ receptor and the evidence obtained from primary human cells, immortalized cell lines, and animal models of inflammation. Finally, we discuss the possible therapies targeting the CB₂ receptor and the questions that remain to be addressed to determine whether this receptor could be a potential target to treat inflammatory disease.

Keywords CB₂ receptor · Cannabinoid · Endocannabinoid · Inflammation · Leukocytes

Abbreviations

2-AG	2-Arachidonoyl-glycerol
AA	Arachidonic acid
AEA	<i>N</i> -Arachidonoyl-ethanolamide
AM1241	(2-Iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone
AM630	6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl(4-methoxyphenyl)methanone
CB65	<i>N</i> -Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide
cAMP	Cyclic adenosine monophosphate
CBD	Cannabidiol
CBG	Cannabigerol
CBN	Cannabinol
COX	Cyclooxygenase
CP 55,940	(-)- <i>Cis</i> -3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]- <i>trans</i> -4-(3-hydroxypropyl)cyclohexanol
Δ ⁹ -THC	(-)-Δ ⁹ -Tetrahydrocannabinol
ERK-1/2	Extracellular signal-regulated kinases-1/2
FAAH	Fatty acid amide hydrolase
GFP	Green fluorescent protein
GIRK	G-protein-coupled inwardly rectifying potassium (channel)
GP 1a	<i>N</i> -(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2- <i>c</i>]pyrazole-3-carboxamide
GP 2a	<i>N</i> -Cyclohexyl-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2- <i>c</i>]pyrazole-3-carboxamide
GPCR	G-protein-coupled-receptor

✉ Nicolas Flamand
nicolas.flamand@criucpq.ulaval.ca

¹ Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département de médecine, Faculté de médecine, Université Laval, Québec, QC G1V 4G5, Canada

HU-210	3-(1,1'-Dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol
HU-308	4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-methanol
IP ₃	Inositol 1,4,5-trisphosphate
JTE 907	<i>N</i> -(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide
JWH 015	(2-Methyl-1-propyl-1 <i>H</i> -indol-3-yl)-1-naphthalenyl-methanone
JWH 133	(6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
L-759,633	(6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
L-759,656	(6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-1-methoxy-6,6-dimethyl-9-methylene-6H-dibenzo[b,d]pyran
LOX	Lipoxygenase
MAG	Monoacylglycerol
MAPK	Mitogen-activated protein kinases
NADA	<i>N</i> -Arachidonoyl-dopamine
PI3K	Phosphoinositide 3-kinase
PKC	Protein kinase C
PLC	Phospholipase C
PTX	Pertussis toxin
SER 601	<i>N</i> -(Adamant-1-yl)-6-isopropyl-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide
WIN 55,212-2	[(3R)-2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate
SR141716A	<i>N</i> -(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 <i>H</i> -pyrazole-3-carboxamide hydrochloride
SR144528	5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]- <i>N</i> -[(1 <i>S</i> ,2 <i>S</i> ,4 <i>R</i>)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1 <i>H</i> -pyrazole-3-carboxamide

Introduction

The psychotropic effects induced by cannabis promoted its widespread use among the population. These effects are mediated by a cannabinoid receptor that is mainly

expressed in the central nervous system, namely CB₁. The identification of a receptor that is selectively activated by cannabinoids suggested that the human body synthesizes at least one natural ligand for this receptor. This hypothesis was confirmed by the discovery of two high-affinity ligands for the CB₁ receptor: arachidonoyl-ethanolamide (AEA) [1] and 2-arachidonoyl-glycerol (2-AG) [2]. As these novel lipid mediators were uncovered, a second cannabinoid receptor (CB₂) was being cloned and characterized. Its expression profile among tissues was found to be distinct from that of CB₁. It was primarily found in immune cells and was initially not detected in the brain, although this was later proven incorrect by several studies. In light of these findings, the CB₂ receptor was postulated to be responsible for the immunomodulatory effects of cannabinoids and endocannabinoids. In the past two decades, this hypothesis was tested in a wide array of cellular and animal models. This article offers a comprehensive review of the evidence that was gathered in these studies, with a focus on peripheral inflammation. The CB₂ receptor's potential as a therapeutic target in inflammatory disease is also discussed.

Cloning of the CB₂ receptor

The non-psychoactive effects of cannabinoids were initially believed to be mediated either centrally or through their interaction with non-receptor proteins. Although there are phytocannabinoids that exert non-psychoactive effects without binding to CB₂ receptor [e.g., cannabidiol (CBD), cannabigerol (CBG)], discovering the latter explained many of the peripheral effects of cannabinoids. Munro et al. cloned the human CB₂ receptor in 1993 from the promyelocytic leukaemic cell line HL-60 [3]. To achieve this, cells were treated with dimethylformamide to induce granulocyte differentiation, a cDNA library was prepared, polymerase chain reaction (PCR) was performed using degenerated primers, and the amplification products were cloned and sequenced. One of the clones showed homology to the G-protein-coupled-receptor (GPCR) family and was related to the CB₁ receptor. The protein encoded by this sequence was found to have 44 % homology with the CB₁ receptor. This homology increased to 68 % when only the transmembrane portion was considered. Binding assays showed that this receptor had high affinity for the cannabinoid receptor ligands WIN 55,212-2 and CP 55,940, as well as the endocannabinoid AEA and the phytocannabinoid Δ⁹-THC. The authors suggested that the previously described central receptor be named CB₁ and that this novel, peripheral receptor be named CB₂.

A few years later, Shire et al. [4] cloned the murine CB₂ receptor from a mouse splenocyte cDNA library. They found it to be 82 % homologous to the human CB₂ receptor and to have similar affinity for the ligands AEA, CP 55,940, and Δ⁹-THC. WIN 55,212-2, however, bound the mouse CB₂ receptor with an affinity six-fold lower than that documented for human CB₂. This was followed by the cloning of the rat CB₂ receptor by Brown et al. [5]. The authors also compared the sequence of their clone with those of the mouse and human CB₂ receptor and found significant differences in protein length, although these were mainly the consequence of disparities in carboxyl termini. Amino acid conservation was highest in the transmembrane regions of the three receptors.

In addition to binding the endocannabinoids AEA and 2-AG, the CB₂ receptor binds many phytocannabinoids. The pharmacology of endocannabinoids and that of the CB₂ receptor were rigorously reviewed in the past [6, 7]. Table 1 provides a summary of the various endocannabinoids and phytocannabinoids and their affinity for the human CB₂ receptor.

Available tools to study CB₂ receptor functions

Pharmacological compounds

Synthetic cannabinoids, such as CP 55,940 and WIN 55,212-2, were already available when the CB₂ receptor was cloned. They were subsequently shown to be potent CB₂ ligands, but also to lack selectivity, as they activate CB₁ with comparable efficiency. In this respect, several agonists and antagonists were rapidly developed and made available to the scientific community. The most widely used compounds are the agonist JWH 133, and the antagonists SR144528 and AM630. Still, many compounds display good potency and selectivity towards CB₂. Table 2 contains a comprehensive list of those compounds, as well as their binding potency towards human CB₂, and in some cases, the other receptors they target.

Knockout mice

The first CB₂ receptor-deficient mouse was generated by Buckley et al. in 2000 [32]. The *CNR2* gene was

Table 1 Binding of endocannabinoids and phytocannabinoids to the human CB₂ receptor

	<i>K_i</i> (nM)	Model	References
Endocannabinoid			
AEA	371	CHO cells	[8]
	1940	AtT-20 cells	[9]
	795	Sf9 cells	[10]
	3500	CHO cells	[10]
2-AG	949	Sf9 cells	[10]
	650	CHO cells	[10]
Dihomo-γ-LEA	857	AtT-20 cells	[9]
Oleamide	>100,000	HEK-293 cells	[11]
NADA	12,000 ^b	Rat spleen	[12]
2-AG-ether	>3000 ^a	COS-7 cells	[13]
Phytocannabinoid			
Δ ⁹ -THC	34.6	CHO cells	[8]
Δ ⁸ -THC	39.3	Mouse spleen	[14]
CBN	96.3	CHO cells	[8]
	301	AtT-20 cells	[9]
CBD	2680	CHO cells	[8]
β-Caryophyllene	155	HEK293 cells	[15]

K_i values were obtained in function of [³H]CP 55,940 displacement unless indicated otherwise

NADA *N*-arachidonoyl-dopamine, CBN cannabinol

^a [³H]HU-243

^b [³H]WIN55212-2

Table 2 CB₂ agonists and antagonists

	K _i (nM)	Other targets	References
Agonist			
AM 1241	3.4	TRPA1	[16, 17]
JWH 133	3.4	TRPV1	[18, 19]
GW 405833	3.6–3.92	–	[20]
JWH 015	13.8	–	[8]
HU 308	22.7	–	[21]
L-759,633	6.4	–	[22]
L-759,656	11.8	–	[22]
SER 601	6.3	–	[23]
GP 1a	0.037	–	[24]
GP 2a	7.6	–	[24]
CB 65	3.3	–	[25]
HU 210	0.061–0.52	CB ₁ , GPR55, 5-HT ₂	[9, 26, 27]
CP 55,940	0.6–5.0	CB ₁ , GPR55	[26, 28]
WIN 55, 212-2	62.3	CB ₁ , TRPA1	[9, 17, 28]
Antagonist			
SR144528	0.6–4.1	–	[22, 29]
AM 630	5.6–31.2	TRPA1	[22, 30]
JTE907	35.9	–	[31]

– This compound is not known to activate other receptors besides CB₂
TRP transient receptor potential ion channel

inactivated by homologous recombination, by replacing a 341 bp fragment of its coding sequence with the neomycin gene. This mutation eliminated part of intracellular loop 3, transmembrane domains 6 and 7, and the carboxyl extremity of the receptor. Autoradiography experiments confirmed the absence of specific binding of [³H]CP 55,940 in the spleen of CB₂^{-/-} mice. No significant difference in the binding of [³H]CP 55,940 between wild-type and knockout animals was found in the brain, supporting that CB₁-receptor expression was not altered in CB₂^{-/-} animals. The authors confirmed this by demonstrating that knockout mice were as responsive to the psychotropic effects of Δ⁹-THC as wild-type animals.

CB₂^{-/-} mice display no morphological differences when compared to their wild-type counterparts. They are normal size and weight, are fertile, have normal litter sizes and care for their young. However, subsequent studies by other groups show that CB₂^{-/-} mice develop differences at the cellular level. In this regard, Ofek et al. have demonstrated that CB₂^{-/-} mice have lower counts of osteoblast precursors and increased numbers and activity of osteoclasts [33]. In consequence, these mice have a low bone mass phenotype that worsens with age. They also present abnormalities in the development of several T and B cell subsets [34]. While this might impair immune homeostasis, CB₂^{-/-} mice fail to spontaneously develop any observable

immune disease. Therefore, they are suitable to study CB₂ function and have, since, become invaluable tools in cannabinoid research. In this respect, they have been used to define the impact of CB₂ deficiency in a variety of inflammatory disease models, and the results of these studies will be discussed in the section entitled **CB₂ activation by endocannabinoids in vivo**

Antibodies

As it is the case with numerous GPCRs, CB₂ protein detection is difficult due to the lack of specificity of primary antibodies. This concept was underscored in a recent study by Marchalant et al. [35], who showed that a commercially available and widely used CB₂ polyclonal antibody is heavily cross-reactive towards other proteins. Noteworthy, they demonstrated that some of the proteins detected by the antibody were not membrane-bound, ruling out the previously suggested hypothesis that the additional bands represent glycosylation variants of the CB₂ receptor. Moreover, Graham et al. [36] compared several CB₂ primary antibodies in flow cytometry experiments on human primary leukocytes. The antibodies which they compared generated different expression patterns between cell types. Therefore, data regarding CB₂ protein detection must be interpreted with caution.

The detection of the CB₂ receptor using antibodies can be substituted, to some extent, by the alternate methods. For example, Schmöle et al. [37], recently, generated a bacterial artificial chromosome (BAC) transgenic mouse model that expresses a green fluorescent protein (GFP) under the CB₂ promoter. This mouse can be used to determine CB₂ expression in mouse tissues *in vitro* and *in situ*, by several techniques, including RT-PCR, qPCR, immunoblot, flow cytometry, and immunofluorescence. This system, based on GFP detection, is an alternative to the use of CB₂ antibodies on mouse tissues. It is more reliable in the sense that most antibodies directed against GFP are specific and yield reproducible data. However, this kind of approach cannot be used for CB₂ detection in human primary cells and tissues, which remain problematic. A different strategy that was evaluated by Petrov et al. involves the synthesis of fluorescent CB₂ agonists [38]. The synthesized compound showed marked selectivity for CB₂ over the CB₁, 5-HT_{2A}, and 5-HT_{2C} receptors. This agonist was validated as a flow cytometry probe to detect the CB₂ receptor in cells, and also to evaluate CB₂-receptor binding using fluorescence microscopy. Other methods of detection could also be added to CB₂ ligands to use them as probes, such as biotinylation [39].

CB₂ expression profiles in human and animal tissues

Expression profile of CB₂ among tissues

Upon cloning the human CB₂ receptor from HL-60 cells, Munro et al. isolated a portion of a rat homologue by PCR [3]. They used this homologue to probe various rat tissues and detected high CB₂ receptor mRNA levels in the spleen, but not in the liver, nasal epithelium, thymus, brain, lung, or kidney. Cell sorting allowed the authors to associate CB₂ receptor expression to the monocyte/macrophage population of the spleen rather than T cells. Two years later, Galiègue et al. published the first study describing CB₂ receptor expression in various human tissues and isolated leukocyte populations [40]. The authors found high CB₂ mRNA levels in tonsils, spleen, PBMC, and thymus, and were able to detect the CB₂ protein in tonsils by immunohistochemistry using an anti-CB₂ polyclonal antibody. They also evaluated CB₂ receptor mRNA expression in numerous human organs and found it to be absent from most non-immune tissues, with the exception of pancreas, lung, and uterus, which had relatively low mRNA levels. Several reports have, since, shown that the CB₂ receptor is expressed in both male [41] and female [42, 43] reproductive tissues. In this regard, the CB₂ receptor exerts an important role in the fertility of both sexes, which has already been extensively reviewed [44–47].

The pattern of CB₂ receptor expression among human tissues is consistent between studies. More groups have reported the presence of the CB₂ receptor mRNA and protein in the human spleen [48] and tonsils [49]. Moreover, the high level of CB₂ expression in human immune tissues was also reported in murine and rodent spleen [37, 50–56] and thymus [37, 54].

The presence and role of the CB₂ receptor in the central nervous system have yet to be fully elucidated, and the issue was discussed in a review article recently published by Atwood and Mackie [57]. It was initially believed that it was not expressed in non-immune cells of the central nervous system, because Munro et al. did not detect CB₂ receptor mRNA in any brain part when they cloned the receptor [3], which is supported by many studies [40, 54, 58, 59]. However, we now know that the CB₂ receptor is not completely absent from the brain, since it is expressed in microglia [60]. Still, the concept of the CB₂ receptor being a second central cannabinoid receptor is up to debate for three main reasons: (1) a study showed that the CB₂ receptor agonists JWH-015 and JWH-133 modulate peripheral neuron functions [61] and (2) the CB₂ receptor was detected in the uninjured brain by immunohistochemistry on numerous occasions [62–64], and (3) a recent study found that hippocampal principal neurons express CB₂ mRNA, and that CB₂-selective agonist HU-308 modulated the activity of these cells [65]. Conversely, a study that relied on GFP detection to determine the expression of the CB₂ receptor in the murine brain showed that the signal is located in microglia [37]. Therefore, the lack of reliability of the antibodies that were used in immunohistochemistry experiments stresses the need for more research to expand our knowledge on the involvement of the CB₂ receptor in the central nervous system and neuroinflammation.

In 2009, Liu et al. showed that two distinct isoforms of the CB₂ receptor exist [66]. The novel CB₂ isoform was a splicing variant of the earlier cloned receptor, and was identified from a human neuroblastoma cDNA library. Splicing variants were also discovered in mice and rats, although their genomic structures and transcripts were different from those found in humans. Furthermore, the two human variants were found to display tissue-specific expression patterns. While the classical CB₂ isoform was predominantly found in spleen and other immune tissues, the novel isoform was detected in higher levels in testis and brain regions of the reward system. The identification of this new CB₂ variant could shed some light on the confusing expression patterns that were previously reported. Finally, it underscores the possibility of a role for CB₂ in reproductive and central nervous systems that are distinct from the immunomodulatory role of the classical CB₂ isoform.

CB₂ expression in immune cells

It is well known that the CB₂ receptor is widespread among cells of the immune system. Table 3 provides the literature associated with the expression of the CB₂ receptor in human leukocytes. Every cell type that has been investigated was found to express both mRNA and protein in at least one report. However, there is conflicting data associated with a few cell types. For example, there is no consensus in the literature regarding the presence of the CB₂ receptor in human neutrophils. Of note, not every study was conducted on purified, eosinophil-depleted neutrophils. Given that eosinophils have very abundant amounts of CB₂ receptor mRNA, a small number of eosinophils among the neutrophil sample could result in a false positive. This is consistent with the observation that CB₂ levels are lower in neutrophils than in eosinophils.

As discussed in the previous section, the scientific community should always be critical when interpreting protein data, especially of GPCRs. A large number of researchers have now reported expression data obtained

with commercially available antibodies, and most of them relied on a positive control to validate their results. It was later underscored that in the case of the CB₂ receptor, a reliable negative control is absolutely necessary to confirm that the signal is not generated by non-specific binding of the antibody [35, 67].

CB₂ receptor signaling

The CB₂ receptor was associated to the GPCR family when it was cloned. However, the signal transduction pathways induced by CB₂ receptor activation are far less characterized than those of CB₁. CB₁ is known to inhibit adenylyl cyclase, to modulate ion channels, and to activate numerous downstream signaling events, including p38 and p42/44 MAPK (ERK-1/2), PI3K, calcium mobilization (phospholipase C/IP₃), the arachidonic acid cascade, and nitric oxide production (reviewed in [83]). A few studies have aimed to compare the signaling events of CB₁ and CB₂ in a given cell system and found some divergences between the

Table 3 CB₂ receptor expression in human leukocytes

Cell types	Data	CB ₂ expression	References
B cells	mRNA	+	[36, 40, 68, 69]
	Protein	+	[49, 68, 70]
Basophils	mRNA	+	[71]
Dendritic cells	mRNA	+	[56]
	Protein	+	[56]
Eosinophils	mRNA	+	[71–74]
	Protein	+	[74]
Mast cells	mRNA	+	[71]
Macrophages	mRNA	+	[75]
	Protein	+	[48, 75, 76]
Microglia	mRNA	+	[60]
	Protein	+	[60]
Monocytes	mRNA	+	[36, 40, 68, 75, 77, 78]
	Protein	+	[68, 75, 78]
NK cells	mRNA	+	[36, 40, 69]
	Protein	+	[49]
Neutrophils	mRNA	+	[36, 40, 71]
		–	[72–74]
	Protein	+	[79]
Platelets		–	[74]
	mRNA	+	[71]
	Protein	+	[80]
T cells		–	[81]
	mRNA	+	[36, 40, 68, 69]
	Protein	+	[49, 68, 82]

two receptors. This section recapitulates the evidence regarding the signaling events downstream of the CB₂ receptor.

G_{i/o} protein coupling and adenylyl cyclase inhibition

Like the CB₁, the CB₂ receptor couples with G_{i/o} proteins. This was established by Slipetz et al. who found that in CB₂-transfected Chinese Hamster Ovary (CHO) cells, pretreatment with pertussis toxin (PTX) abolished the effect of cannabinoids on forskolin-induced cAMP production [84]. Other groups using CB₂-transfected cell models found signaling events to be PTX-sensitive, supporting the involvement of G_{i/o} proteins [85, 86]. This interaction was later confirmed in murine microglial cells [87], the murine macrophage cell line J774-1 [88], the human promyelocytic cell line HL-60 [89–91], and human bronchial epithelial cells [92]. Since it has proven to couple to G_{i/o} proteins, the impact of CB₂ activation on adenylyl cyclase activity was also investigated. As expected, adenylyl cyclase was inhibited upon treatment of cells with CB₂ receptor agonists and/or synthetic cannabinoids, resulting in a decrease in intracellular cAMP levels [84, 85, 93, 94].

Potassium channels

As opposed to the CB₁ receptor, the CB₂ receptor does not appear to couple to potassium channels. A study by Felder et al. [9] investigated the possible modulation of inwardly rectifying potassium current (K_{ir}) channels in CB₂-transfected AtT-20 cells. In these cells, activation of the CB₂ receptor with WIN 55,212-2 failed to have an impact on K_{ir}. Another study showed that in *Xenopus laevis* oocytes co-expressing the CB₂ receptor and G-protein-gated inwardly rectifying potassium (GIRK) channels, WIN 55,212-2 failed to induce consistent coupling of the CB₂ receptor to GIRK channels [95]. Of note, the CB₁ receptor was able to couple with GIRK channels and to modulate agonist-induced currents in the same cellular model. This important difference between CB₁ and CB₂ receptors established CB₂ as a functionally distinct receptor.

Mitogen-activated protein kinases (MAPK)

Signal transduction pathways induced by CB₂ receptor activation were first investigated in CB₂-CHO cells by Bouaboula et al. [86]. They found that upon CP 55,940 addition, adenylyl cyclase inhibition was followed by ERK-1/2 phosphorylation. This effect was significantly diminished by the protein kinase C (PKC) inhibitor GF 109203X, suggesting that PKC was involved in MAPK activation. Moreover, they were able to confirm their

findings in HL-60 cells, which express the CB₂ receptor. Another group investigated MAPK activation by various CB₂ ligands in HL-60 cells and found that CP 55,940, 2-AG, and AEA increased ERK-1/2 phosphorylation [89]. This effect was blocked by the CB₂ receptor antagonist SR144528 and was stronger in cells stimulated by 2-AG and CP 55,940 than in those treated with AEA. MAPK activation downstream of CB₂ activation was also demonstrated in vitro in murine osteoblasts [96], in DAUDI leukemia cells [94], murine microglia [97], and human primary monocytes [78]. Finally, this pathway was shown to be activated in vivo, in a mouse model of acute experimental pancreatitis. In this model, a CB₂ receptor agonist reduced inflammation through the p38-MK2 pathway [98].

Intracellular calcium concentrations and phospholipase C activity

A study conducted in calf pulmonary endothelial cells showed that CB₂ activation modulates intracellular calcium concentrations [99]. In this model, AEA initiated phospholipase C (PLC) activation and inositol 1,4,5-triphosphate (IP₃) production, which led to intracellular Ca²⁺ release from the endoplasmic reticulum, as well as an increase in mitochondrial Ca²⁺. This effect of AEA was not mimicked by arachidonic acid (AA), was blocked by SR144528, and was unchanged by treatment with SR141716A, confirming the involvement of the CB₂, but not the CB₁ receptor. Another group later confirmed this in HEK-293 cells co-expressing the CB₂ receptor with chimeric G_i and G_o proteins [100]. In this model, treatment with CP 55,940 or other CB receptor agonists was found to increase intracellular Ca²⁺ levels. The phospholipase C inhibitor U73122 abrogated the effect of CP 55,940 on calcium mobilization, as did thapsigargin. This evidence shows that in these cells, CB₂ receptor activation induces calcium mobilization via the PLC-IP₃ signaling pathway.

In vitro studies of CB₂ receptor functions

CB₂ activation by endocannabinoids in vitro

The endocannabinoids 2-AG and AEA both act on various immune cell types through CB₂ receptor activation (summarized in Table 4). Interestingly, there is a sharp contrast between the anti-inflammatory effects that are triggered by the two lipids. 2-AG was most often found to modulate functions related to leukocyte recruitment, such as chemokine release, adhesion to fibronectin, and migration. This positive regulation of immune cell recruitment by

Table 4 CB₂-mediated effects of endocannabinoids on immune cell functions

Cell type	Species	Endocannabinoid	Effects	References
Anti-inflammatory effects				
Astrocytes	Rat	AEA	↓TNF- α	[103]
Dendritic cells	Human	AEA	↓ IL-6, IL-12 and IFN- α	[104]
Microglia	Mouse (BV-2 cell line)	AEA	↓ Nitric oxide	[105]
	Mouse	AEA	↑ IL-10 ↑ IL-10 ↓ IL-12p70 and IL-23	[106] [107]
Neutrophils	Rat	AEA	LPS-induced nitric oxide release	[108]
	Human	2-AG	↓ fMLP-induced migration	[79]
Splenocytes	Human	AEA	↓ Primary and secondary antibody formation	[109]
T cells (not separated)	Human	AEA	↓ Cell proliferation	[110]
		2-AG	↓ SDF-1-induced migration	[111]
CD4+ T cells	Human	AEA	↓ IL-17, IFN- γ and TNF- α	[110]
CD8 + T cells	Human	AEA	↓ IFN- γ and TNF- α	[110]
	Human	AEA	↓ SDF-1-induced migration	[112]
Pro-inflammatory effects				
B cells	Human	2-AG	↑ Migration	[113]
	Mouse	2-AG	↑ Migration	[114, 115]
Dendritic cells	Human	2-AG	↑ Migration	[116]
Eosinophils	Human	2-AG	↑ Migration	[74, 117]
	Human	2-AG	↑ Migration ↑ LTC ₄ and EXC ₄ synthesis	[101]
Macrophages	Mouse (peritoneal)	2-AG	↑ Zymosan phagocytosis	[118]
	Human (HL-60)	2-AG	↑ Actin polymerization ↑ Adhesion to fibronectin	[119]
				↑ MCP-1 and IL-8
Microglia	Mouse (BV-2 cell line)	2-AG	↑ Migration	[121]
Monocytes	Human	2-AG	↑ Adhesion to fibronectin	[122]
			↑ Migration	[119]
NK cells	Human	2-AG	↑ Migration	[123]
T cells	Human (Jurkat)	2-AG	↑ L- and P-selectin ↑ Adhesion and transmigration	[124]

TNF tumor necrosis factor, *IL* interleukin, *IFN* interferon, *LPS* lipopolysaccharide, *fMLP* formyl-Met-Leu-Phe, *SDF* stromal cell-derived factor, *LTC₄* leukotriene C₄, *EXC₄* eoxin C₄, *MCP* monocyte chemoattractant protein

2-AG is the main pro-inflammatory effect of endocannabinoids or cannabinoids in vitro that has been reported. AEA, on the other hand, was found to down-regulate leukocyte functions, such as pro-inflammatory cytokine release and nitric oxide production. A few reports also show increased production of the anti-inflammatory cytokine IL-10 by cells treated with AEA. In all cases, the involvement of the CB₂ receptor was confirmed by the use of a selective antagonist. However, it is still possible that endocannabinoid metabolites are involved in the reported effects. Noteworthy, this hypothesis was tested in human eosinophils which were shown to migrate in response to

2-AG [101]. In this model, the effect of 2-AG on eosinophil transmigration was blocked by the pre-incubation of cells with a CB₂ receptor antagonist. However, a CB₂-selective agonist failed to mimic the impact of 2-AG, and its 15-LO-derived metabolites were suggested to be necessary for eosinophils to migrate. Therefore, the successful blockade of endocannabinoid-induced effects with a CB₂ antagonist does not always rule out the possibility that other mediators, notably endocannabinoid metabolites, are involved as well [102]. This concept could explain why endocannabinoids can induce both pro- and anti-inflammatory effects.

CB₂ activation by exogenous agonists in vitro

In contrast to endocannabinoids, CB₂ receptor agonists have only been shown to exert anti-inflammatory effects on leukocytes, which are detailed in Table 5. Some of the studies were performed using a non-selective cannabinoid, but the involvement of the CB₂ receptor was always confirmed with an antagonist. In addition to downregulating leukocyte functions, such as cytokine release, reactive oxygen species production and migration, CB₂ agonists

limited HIV-1 expression, and replication in human macrophages and microglia [75, 125].

In vivo studies of CB₂ receptor functions

Impact of CB₂ knockout in inflammation models

Transgenic mice have greatly contributed to our understanding of this receptor's role in human disease, including

Table 5 Effects of CB₂ agonists on immune cell functions

Cell type	Species	Agonist	Effects	References
Astrocytes	Human	WIN 55,212-2	↓ Nitric oxide ↓ TNF- α , IL-10, MCP-1 and CCL5	[126]
Dendritic cells	Mouse	Δ^9 -THC	↑ NF- κ B-dependent apoptosis	[127]
		GP1a	↓ MMP-9 ↓ Migration	[128]
Monocytes	Human	JWH-015	↓ CCL2 and CCL3-induced migration	[78]
		HU-308	↓ TNF- α -induced transendothelial migration	[129]
		JWH-133		
Macrophages	Human (monocyte-derived)	JWH-133	↓ Expression of 35 genes upregulated by LPS	[130]
		JWH-133	↓ HIV-1 replication	[75]
		GP1a		
	Mouse (RAW264.7)	O-1966		
		WIN 55,212-2	↓ Reactive oxygen species ↓ Nitric oxide	[131] [132]
		Δ^9 -THC	↓ RANTES-induced migration	[133]
Mast cells	Rat (RBL-2H3)	JWH-133	↑ IL-10	[134]
		Δ^9 -THC	↓ IL-12p40	
		WIN 55,212-2	↓ Activation of CD4+ T cells	[59]
		CP 55,940	↓ β -Hexosaminidase release	[135]
Microglia	Human	WIN 55,212-2	↓ HIV-1 expression	[125]
	Rat	JWH-015	↓ LPS-induced TNF- α production ↓ Migration	[136]
Neutrophils	Mouse	JWH-133	↓ MIP-2 α -induced migration	[137]
	Human	JWH-133	↓ TNF- α -induced MMP-9 release	[138]
Splenocytes	Human	Δ^9 -THC	↓ Primary and secondary antibody formation	[109]
T cells	Human	Δ^9 -THC	↓ Th2 cytokine production	[139]
		CP 55,940	↓ SDF-1-induced migration	[140]
	Human (Jurkat)	WIN 55,212-2		
		JWH-015		
Mouse	O-1966	↓ NF- κ B activation ↑ SOCS5 expression	[141]	
		↑ IL-10		
	JWH-015	↓ SDF-1-induced migration	[140]	

CCL chemokine (C-C motif) ligand, NF- κ B nuclear factor kappa-light-chain-enhancer of activated B cells, MMP matrix metalloproteinase, MIP macrophage inflammatory protein, HIV human immunodeficiency virus, SOCS suppressor of cytokine signaling

inflammatory conditions. In this regard, several models have shown that mice that are lacking the CB₂ receptor have exacerbated inflammation (summarized in Table 6). The effects that were usually observed in CB₂^{-/-} animals included increased leukocyte recruitment (often neutrophils) and pro-inflammatory cytokine production, which often caused tissue damage. Conversely, one study found CB₂-deficient mice to be in better condition than the wild-type group [142]. However, the model was cecal ligation-induced sepsis, a condition in which efficient bacterial clearance by the immune system is vital. The authors' observations that the CB₂^{-/-} group had less mortality and less bacterial invasion was explained by the lower levels of IL-10 in these mice, which might have led to a better phagocytic response. Overall, these findings are consistent with the other reports of increased immune cell functions in the absence of the CB₂ receptor.

CB₂ activation by exogenous agonists in vivo

The potential of activating CB₂ in vivo to treat inflammation has been investigated in numerous studies. Two main strategies are employed: (1) the administration of a CB₂ receptor agonist; and (2) the administration of an endocannabinoid hydrolysis inhibitor to augment endocannabinoid signaling.

The administration of CB₂ receptor agonists has been performed in several inflammation models. Table 7 summarizes the data that were generated with this approach. In many instances, the chosen agonist was not CB₂-selective and targeted both cannabinoid receptors, in which case, the involvement of CB₂ was confirmed by showing that the treatment of animals with a CB₂ antagonist abrogated the

effects of the cannabinoid receptor agonist. Altogether, the results of those studies point to the conclusion that CB₂ activation improves inflammation in mice. The recruitment of leukocytes to tissues and the production of pro-inflammatory cytokines and reactive oxygen species were downregulated in various inflammation models. In the case of atherosclerosis, two studies showed not only a decrease in inflammatory cells and mediators upon cannabinoid treatment, but also a slower progression of the disease [148, 149]. Indeed, oral Δ⁹-THC administration, at doses that are suboptimal for inducing psychotropic effects, resulted in reduced atherosclerotic lesion development. Since these effects of Δ⁹-THC were shown to be mediated by the CB₂ receptor, this supports that a selective CB₂ receptor agonist might be a valuable tool for the treatment of atherosclerosis.

CB₂ activation by endocannabinoids in vivo

The most widely used approach to investigate the impact of endocannabinoids in vivo is the blockade of their hydrolysis, as it is an efficient way to increase their levels in tissues. Despite the numerous studies that have used this method in animal models, it is still unclear whether the effects of endocannabinoids are pro- or anti-inflammatory. This is due, in part, to the presence of numerous enzymes that can metabolize them into other bioactive lipids. The main pathway is hydrolysis into AA by lipases, such as MAG lipase for 2-AG [164] and FAAH for AEA [165]. AA is a precursor for the biosynthesis of leukotrienes, prostaglandins, and other lipid mediators of inflammation. Alternatively, endocannabinoids can undergo oxidation

Table 6 Anti-inflammatory effects of CB₂ receptor deletion in inflammation models

Model	Species	Genotype	Effects	References
DNFB-induced hypersensitivity	Mouse	CB ₂ ^{-/-}	↑ Neutrophil recruitment ↑ Ear swelling	[143]
Hepatic ischemia–reperfusion injury	Mouse	CB ₂ ^{-/-}	↑ Neutrophil recruitment ↑ Inflammatory cytokines ↑ Liver damage	[144]
TNBS-induced colitis	Mouse	CB ₂ ^{-/-}	↑ Colitis ↑ TNF-α and IL-1β	[145]
Myocardial ischemia–reperfusion injury	Mouse	CB ₂ ^{-/-}	↑ Neutrophil and macrophage infiltration ↓ IL-10	[146]
Traumatic brain injury	Mouse	CB ₂ ^{-/-}	↑ TNF-α, iNOS and ICAM mRNA ↑ Blood–brain barrier permeability	[147]
Cecal ligation-induced sepsis	Mouse	CB ₂ ^{-/-}	↓ IL-10 ↓ Bacterial invasion ↓ Mortality	[142]

DNFB 2,4-dinitrofluorobenzene, TNBS trinitrobenzenesulfonic acid, iNOS inducible nitric oxide synthase, ICAM intercellular adhesion molecule

Table 7 Anti-inflammatory effects of CB₂ agonists in animal models of inflammation

Model	Species	Treatment	Effects	References
Atherosclerosis	Mouse	Δ ⁹ -THC	↓Atherosclerotic lesions ↓ Macrophage infiltration ↓ Leukocyte adhesion	[149]
		WIN 55,212-2	↓Atherosclerotic lesions ↓ Macrophage infiltration ↓ MCP-1, IL-6 and TNF-α	[148]
Breast cancer cell injection	Mouse	Δ ⁹ -THC	↓ Splenocyte proliferation	[150]
Brain ischemia	Mouse	JWH-133	↓ Microglia and macrophage infiltration	[151]
			↓ IL-6, MCP-1, MIP-1α, CCL-5 and TNF-α ↓ iNOS	
Experimental autoimmune encephalomyelitis	Mouse	Δ ⁹ -THC	↓ Monocyte recruitment	[152]
		JWH-133	↓ IFN-γ and IL-2 ↓ T cell proliferation	
Hepatic ischemia–reperfusion injury	Mouse	Δ ⁸ -THCV	↓ Hepatic injury	[153]
			↓ CCL3, CXCL2 and TNF-α ↓ Neutrophil infiltration	
Germinal matrix hemorrhage-induced neuroinflammation	Rat	JWH-133	↓ TNF-α ↓ Microglia accumulation	[154]
<i>L. pneumophila</i> infection	Mouse	Δ ⁹ -THC	↓ IFN-γ and IL-12	[155]
Influenza virus infection	Mouse	Δ ⁹ -THC	↓ Lymphocyte and monocyte recruitment	[156]
			↓ Viral hemagglutinin	
Myocardial ischemia–reperfusion injury	Mouse	WIN 55,212-2	↓ Myeloperoxidase	[157]
			↓ IL-1β and IL-8	
Ovalbumin-induced asthma	Guinea pig	CP 55,940	↓ Myeloperoxidase	[158]
			↓ Mast cell degranulation ↓ TNF-α and PGD ₂	
LPS-induced interstitial cystitis	Mouse	JWH-015	↓ Leukocyte infiltration	[159]
			↓ Myeloperoxidase ↓ TNF-α, IL-1α and IL-1β	
Sepsis	Mouse	HU308	↓ Adherent leukocytes in submucosal venules	[160]
Spinal cord injury	Mouse	O-1966	↓ Leukocyte infiltration	[161]
			↓ CXCL9 and CXCL11 ↓ IL-23p19 and IL-23R ↓ TLR expression	
Stress-induced neuroinflammation	Mouse	JWH-133	↓ TNF-α and MCP-1	[162]
			↓ COX-2, iNOS and NF-κB	
Traumatic brain injury	Mouse	O-1966	↓ Microglia and macrophage infiltration	[163]
			↓ Blood–brain barrier disruption	

PGD₂ prostaglandin D₂, COX-2 cyclooxygenase-2

and the biological effects of the metabolites that originate from these pathways are not very well characterized [166]. Therefore, it is not possible to conclude that endocannabinoids exert their effects through CB₂ in an inflammation model unless this is confirmed by the genetic or pharmacological blockade of the receptor. In this

respect, Table 8 only presents studies that have thoroughly confirmed the involvement of the CB₂ receptor in the effects they observed.

A limited number of studies reported pro-inflammatory effects of endocannabinoids in vivo, and only three of those (listed in Table 9) were confirmed to involve the

Table 8 Anti-inflammatory effects of CB₂ activation by endocannabinoids in mouse models of inflammation

Model	Treatment	Effects	References
ConA-induced hepatitis	AEA	↓ Inflammatory cytokines	[144]
Carrageenan-induced acute inflammation	URB602	↓ Edema	[167]
Experimental autoimmune encephalomyelitis	WWL70	↓ Nociception	[168]
		↓ iNOS, COX-2, TNF- α and IL-1 β	
		↓ T cell infiltration	
		↓ Microglial activation	
LPS-induced acute lung injury	JZL184	↓ NF- κ B activation	[169]
	↓ Leukocyte infiltration		
LPS-induced inflammatory pain	FAAH KO	↓ BALF cytokines and chemokines	[170]
	↓ Edema		
Kaolin and carrageenan-induced osteoarthritis	FAAH KO, PF-3845, URB597 or OL-135 URB597	↓ TNF- α and IL-1 β	[171]
		↓ Allodynia	[172]
		↓ Leukocyte rolling	[172]
TNBS-induced colitis	JZL184	↓ Microvascular perfusion	[173]
		↓ Submucosa edema	
		↓ Leukocyte infiltration	
		↓ Mucosal IL-6 and IL-1 β	
		↓ Circulating inflammatory markers	

ConA concanavalin A, *BALF* bronchoalveolar lavage fluid

Table 9 Pro-inflammatory effects of CB₂ signaling in mouse models of inflammation

Model	Treatment	Effects	References
Primary immunization	2-AG	↑ Delayed-type hypersensitivity	[116]
TPA-induced ear inflammation	SR144528	↑ DC migration to draining lymph nodes	[179]
		↓ Neutrophil recruitment	
		↓ Swelling	
Oxazolone-induced dermatitis	SR144528	↓ LTB ₄ synthesis	[175]
		↓ Eosinophil recruitment	
		↓ Swelling	
		↓ MCP-1, MIP-1 and TNF- α	

TPA 12-*O*-tetradecanoylphorbol-13-acetate

CB₂ receptor. In two models of dermatitis in mice, treatment with the CB₂ antagonist SR144528 improved inflammation by inhibiting granulocyte recruitment and pro-inflammatory mediator production [174, 175]. In both cases, this translated in a measurable decrease in swelling. As presented above in Table 6, 2-AG has been implicated in the recruitment and migration of B and T cells, dendritic cells, eosinophils, monocytes, and natural killer cells in a CB₂-dependent manner, which could very well translate to in vivo studies. However, to this day, there is no published data demonstrating that exogenous cannabinoids and selective CB₂ receptor agonists have pro-inflammatory effects. Therefore, it is possible that the

pro-inflammatory effects of endocannabinoids that are presented in Table 9 are a result of CB₂ activation and/or the action of one or more endocannabinoid metabolites [102].

Of note, many disorders cause a change in CB₂ receptor protein levels, due to pre-existing pro-inflammatory conditions. In multiple sclerosis and amyotrophic lateral sclerosis, for instance, the expression of CB₂ in microglia is increased, both in human tissues and mouse models [176, 177]. A similar effect was reported in a rodent model of neuropathic pain [178]. This certainly facilitates the impact of CB₂ receptor activation by exogenous agonists of endocannabinoids in these inflammation models.

The CB₂ receptor as a potential therapeutic target

While there is a large body of evidence supporting that CB₂ receptor activation has anti-inflammatory effects, it has yet to be targeted to treat human disease. In the two previous sections, we presented *in vitro* and *in vivo* studies that suggested a role for the CB₂ receptor in numerous inflammatory conditions. In this section, we discuss the potential of the CB₂ receptor as a target in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease.

Potential in rheumatoid arthritis

Rheumatoid arthritis (RA) is an inflammatory disease that affects approximately 1 % of the adult population worldwide. RA is characterized by chronic inflammation of the synovium, cartilage destruction, and bone loss. Patients with RA exhibit an influx of innate (neutrophils, macrophages) and adaptive (lymphocytes) immune cells in the synovial cavity. These cells promote inflammation and connective tissue damage by producing cytokines (TNF- α , IL-6, IL-1 β), pro-inflammatory lipids, and metalloproteinases (MMPs). The synovial lining becomes hyperplastic and an invasive structure (the pannus) is formed. Osteoclasts become exaggeratedly activated and cause bone resorption [180].

2-AG and AEA are present in the synovial fluid of patients with RA, but not healthy volunteers, suggesting an involvement of the endocannabinoid system in the disease. CB₁ and CB₂ mRNA and proteins were also found in the synovial tissues of RA patients [181]. CB₂ activation can inhibit the production of pro-inflammatory cytokines and MMP release from fibroblast-like synoviocytes (FLSs) [182, 183]. It can also promote osteoblast differentiation *in vitro* [33, 184] and inhibit FLS proliferation [182]. These observations indicate that CB₂ receptor activation in RA joints could improve multiple aspects of the disease, including inflammation, FLS hyperplasia, and bone loss.

In vivo, CB₂ agonists have proven to be beneficial in a murine model of rheumatoid arthritis, collagen-induced arthritis (CIA). One study showed treatment with the CB₂ receptor agonist JWH 133 to improve arthritis severity and to reduce bone destruction and leukocyte infiltration in the joints [183]. Another group investigated the impact of a different CB₂-selective agonist, HU-308. They found that the agonist decreased swelling, synovial inflammation, and joint destruction, in addition to lowering circulating antibodies against collagen II [185]. Finally, the agonist HU-320 ameliorated established CIA [186]. Of note, CB₂ agonists did not prevent the onset of RA in any of those

reports, as there were no differences in disease incidence between groups.

This growing body of evidence establishes the CB₂ receptor as a promising target for the treatment of RA. In all three of the above-mentioned studies, the CIA model was used to test CB₂ agonists. Given that there is no animal model of RA that perfectly duplicates all aspects the human condition, these findings should be confirmed in different models.

Potential in atherosclerosis

Atherosclerosis is an inflammatory disease that is characterized by the presence of arterial plaques. These lesions contain immune cells, lipid-laden macrophages (foam cells), cholesterol, smooth muscle cells, and collagen fibres [187]. The physical rupture of the plaques causes the occlusion of arteries, which can lead to tissue infarction. Plaque development is influenced by inflammatory mediators, such as cytokines and chemokines, which are crucial to the recruitment of immune cells to the intima. In this respect, therapies that would downregulate the production of these mediators could reduce the progression of atherosclerotic lesion development. Since the CB₂ receptor is known to decrease the production of numerous chemokines and to inhibit leukocyte migration *in vitro* and *in vivo*, it emerged as a potential target to treat atherosclerosis.

A recent study specifically aimed to characterize the endocannabinoid system in human foam cells [188]. The authors found that the CB₂ agonist JHW-015 significantly decreased oxLDL accumulation in these macrophages. Moreover, it reduced the production of TNF- α , IL-6, and IL-10 and the expression of CD36, a scavenger receptor that is responsible for the uptake of modified lipoproteins by macrophages and the induction of foam cell formation. The endocannabinoids 2-AG and AEA mimicked these effects, which were block by the CB₂ antagonist SR144528. These findings are in accordance with a previous study which showed that CB₂ activation by WIN 55,212-2 reduces the oxLDL-induced inflammatory response in rat macrophages [131].

As briefly discussed in the section entitled [In vivo studies of CB₂ receptor functions](#), the role of the CB₂ receptor was investigated in mouse models of atherosclerosis. The first study to demonstrate the benefits of CB₂ activation in atherosclerosis was performed in *ApoE*^{-/-} mice using low doses of the cannabinoid Δ^9 -THC, which diminished inflammation and blocked the progression of the disease [149]. These effects were prevented by SR144528, confirming the involvement of the CB₂

receptor. The anti-atherosclerotic effects of CB₂ in the *ApoE*^{-/-} model were later confirmed with WIN 55,212-2 as an agonist, and the antagonist AM630 confirmed the mechanism to be CB₂-dependent [148, 189]. In *Ldlr*^{-/-}-CB₂^{-/-} double knockout mice, lesional macrophage and smooth muscle cell contents were higher than in *Ldlr*^{-/-}-CB₂^{+/+} animals [190]. In *Ldlr*^{-/-} mice deficient for CB₂ in hematopoietic cells only, plaque area after 12 weeks on an atherogenic diet was larger than in mice with no CB₂ deficiency [191].

In summary, a large body of evidence strongly suggests that CB₂ receptor activation is an appropriate target for atherosclerosis treatment. CB₂ agonists have the potential to be beneficial on many levels, as they were shown to improve inflammatory cell recruitment and activation, lipid uptake by macrophages, and the size of atherosclerotic plaques. However, a few reports show conflicting data, especially in the *Ldlr*^{-/-} model. A report shows unaltered lesion size following WIN 55,212-2 treatment in this model, although CB₂ receptor activation did decrease lesional macrophage accumulation [192]. Another group treated *Ldlr*^{-/-} mice with JWH-133 and found no significant effect on lesion size or on their content in macrophages, lipids, smooth muscle cells, collagen, and T cells [193]. More investigation is required to determine the causes of these discrepancies before moving forward in the development of therapies targeting CB₂ for atherosclerosis.

Potential in inflammatory bowel disease

Inflammatory bowel disease (IBD) includes two main conditions: ulcerative colitis and Crohn's disease. They are caused by an excessive immune response and can affect any part of the gastrointestinal tract [194]. The endocannabinoid system first gained interest in IBD pathophysiology in light of a study that described a protective effect of CB₁ in DNBS-induced colitis [195]. Cannabinoids were then shown to enhance epithelial wound healing in a CB₁-dependent fashion [76]. The authors of the latter study also evaluated the expression of cannabinoid receptors in human IBD tissue by immunohistochemistry. They found that the CB₁ receptor was expressed in the normal human colon, but that CB₂ expression was higher in IBD tissues and that its presence was concentrated in plasma cells and macrophages. These findings raised the hypothesis that the CB₂ receptor was also involved in the inflammatory component of IBD.

A subsequent study reported that a FAAH inhibitor decreased inflammation in the TNBS-induced colitis model, and that the deletion of either CB₁ or CB₂ abrogated this effect [196]. In the same colitis model, the use of the MAG lipase inhibitor JZL184 to increase 2-AG levels also inhibited the development of colitis [173]. Mice treated

with JZL184 had less colon alteration and lower expression of pro-inflammatory cytokines, and these effects were abolished by the antagonists AM251 (CB₁) and AM630 (CB₂).

Several groups tested the impact of a CB₂ receptor agonist in the IBD models. The CB₂-selective agonists JWH-133 and AM1241 both protected against TNBS-induced colitis, whereas AM630 worsened it [197]. The non-psychotropic cannabinoid cannabigerol (CBG) was tested in DNBS-induced colitis and was found to reduce the colon weight/colon length ratio (an indirect marker of inflammation), MPO activity, and iNOS expression by a CB₂-dependent mechanism [198]. Finally, the plant metabolite and unconventional CB₂ agonist (*E*)-β-caryophyllene (BCP) was also evaluated in a model of DSS-induced colitis. Oral administration of BCP decreased micro- and macroscopic colon damage, MPO activity, NF-κB activation, and pro-inflammatory cytokine production [199].

This wide array of CB₂ receptor agonists being able to improve IBD in animal models prompted the development of highly selective compounds that could be used to treat the disease in humans. In this regard, a research group synthesized a series of CB₂-selective agonists and tested the resulting lead compounds in models of experimental colitis [200, 201]. Intra-peritoneal injection of the agonists was effective at protecting mice against colitis. Of note, a selective compound that is orally effective in experimental colitis was later synthesized [202].

Conclusion

In light of the evidence that was generated over the past two decades by the scientific community, we can draw a few general conclusions regarding the role of the CB₂ receptor. First, it is mainly found in immune tissues and is expressed in most immune cell types. Second, its deletion in animals usually causes an exacerbated inflammatory phenotype in several models, due to an upregulation of immune cell functions. Third, CB₂ activation by cannabinoids, either in vitro or in vivo, usually decreases inflammatory cell activation. Finally, the administration of CB₂ agonists in animal models of inflammatory disease can slow the progression of some diseases, in addition to reducing inflammation.

Several questions still need to be investigated. For example, there is no consensus regarding the expression of the CB₂ receptor in non-immune brain cells, and the role that CB₂ might play in brain functions is unknown. Moreover, the impact of endocannabinoids on immune cells is still unclear. While most animal studies show that the blockade of endocannabinoid hydrolysis results in less inflammation, it is not possible to tell whether these effects

are caused only by CB₂ activation and whether the opposite would occur in humans. In this respect, endocannabinoids can induce human leukocyte migration (Table 4). However, the impact of endocannabinoid metabolites on leukocyte functions is not well defined, and this should be addressed before endocannabinoid hydrolysis inhibitors that can be considered as a valid strategy to enhance CB₂ receptor signaling [102]. Finally, the few CB₂ agonists that are currently being developed aim at treating inflammatory pain [203–205]. Perhaps, these novel compounds are worthy of sparking new studies to define their putative beneficial role in inflammatory diseases.

Acknowledgments This work is/was supported by Grants to NF from the Canadian Institutes of Health Research (MOP-97930) and The Natural Sciences and Engineering Research Council of Canada. NF also received operating grants from le Fonds sur les maladies respiratoires J.-D. Bégin—P.-H. Lavoie. CT was the recipient of a doctoral award from the Canadian Consortium for the Investigation of Cannabinoids and is currently supported by the Canadian Institutes of Health Research. MRB, ML, and NF are members of the inflammation group of the Respiratory Health Network of the Fonds de recherche en Santé-Québec.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258(5090):1946–1949
- Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50(1):83–90
- Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 365(6441):61–65. doi:10.1038/365061a0
- Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O, Le Fur G, Caput D, Ferrara P (1996) Molecular cloning, expression and function of the murine CB₂ peripheral cannabinoid receptor. *Biochim Biophys Acta* 1307(2):132–136
- Brown SM, Wager-Miller J, Mackie K (2002) Cloning and molecular characterization of the rat CB₂ cannabinoid receptor. *Biochim Biophys Acta* 1576(3):255–264
- Pertwee RG (1997) Pharmacology of cannabinoid CB₁ and CB₂ receptors. *Pharmacol Ther* 74(2):129–180
- Pertwee RG (2015) Endocannabinoids and their pharmacological actions. *Handb Exp Pharmacol* 231:1–37. doi:10.1007/978-3-319-20825-1_1
- Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB₂): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther* 278(3):989–999
- Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB₁ and CB₂ receptors. *Mol Pharmacol* 48(3):443–450
- Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) The Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol* 57(5):1045–1050
- Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB₁ cannabinoid receptors. *Br J Pharmacol* 141(2):253–262. doi:10.1038/sj.bjp.0705607
- Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) *N*-Acyl-dopamines: novel synthetic CB₁ cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. *Biochem J* 351(Pt 3):817–824
- Hanus L, Abu-Lafi S, Frède E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB₁ receptor. *Proc Natl Acad Sci USA* 98(7):3662–3665. doi:10.1073/pnas.061029898
- Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. *Curr Med Chem* 6(8):635–664
- Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A (2008) Beta-caryophyllene is a dietary cannabinoid. *Proc Natl Acad Sci USA* 105(26):9099–9104. doi:10.1073/pnas.0803601105
- Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr (2003) Activation of CB₂ cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. *Proc Natl Acad Sci USA* 100(18):10529–10533. doi:10.1073/pnas.1834309100
- Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM (2008) Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. *J Neurosci* 28(5):1064–1075. doi:10.1523/JNEUROSCI.1565-06.2008
- Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB₂ receptor. *Bioorg Med Chem* 7(12):2905–2914
- McDougall JJ, Yu V, Thomson J (2008) In vivo effects of CB₂ receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. *Br J Pharmacol* 153(2):358–366. doi:10.1038/sj.bjp.0707565
- Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. *Neuropharmacology* 48(5):658–672. doi:10.1016/j.neuropharm.2004.12.008
- Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Frède E (1999) HU-308: a specific agonist for CB₂, a peripheral cannabinoid receptor. *Proc Natl Acad Sci USA* 96(25):14228–14233
- Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999) Agonist-inverse agonist characterization at CB₁ and CB₂ cannabinoid receptors of

- L759633, L759656, and AM630. *Br J Pharmacol* 126(3):665–672. doi:[10.1038/sj.bjp.0702351](https://doi.org/10.1038/sj.bjp.0702351)
23. Pasquini S, Botta L, Semeraro T, Mugnaini C, Ligresti A, Palazzo E, Maione S, Di Marzo V, Corelli F (2008) Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. *J Med Chem* 51(16):5075–5084. doi:[10.1021/jm800552f](https://doi.org/10.1021/jm800552f)
 24. Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessi C, Curzu MM, Chelucci G, Pani L, Pinna GA (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB₂ cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. *J Med Chem* 49(25):7502–7512. doi:[10.1021/jm060920d](https://doi.org/10.1021/jm060920d)
 25. Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F, Saccomanni G, Tuccinardi T, Vannacci A, Martinelli A, Ferrarini PL (2006) Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB₂ selective agonists. *J Med Chem* 49(20):5947–5957. doi:[10.1021/jm0603466](https://doi.org/10.1021/jm0603466)
 26. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol* 152(7):1092–1101. doi:[10.1038/sj.bjp.0707460](https://doi.org/10.1038/sj.bjp.0707460)
 27. Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999) Modification of 5-HT₂ receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. *Neuropharmacology* 38(4):533–541
 28. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. *J Pharmacol Exp Ther* 285(1):285–292
 29. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere JC, Le Fur GL (1998) SR 144528, the first potent and selective antagonist of the CB₂ cannabinoid receptor. *J Pharmacol Exp Ther* 284(2):644–650
 30. Patil M, Patwardhan A, Salas MM, Hargreaves KM, Akopian AN (2011) Cannabinoid receptor antagonists AM251 and AM630 activate TRPA₁ in sensory neurons. *Neuropharmacology* 61(4):778–788. doi:[10.1016/j.neuropharm.2011.05.024](https://doi.org/10.1016/j.neuropharm.2011.05.024)
 31. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB₂ receptor. *J Pharmacol Exp Ther* 296(2):420–425
 32. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB₂ receptor. *Eur J Pharmacol* 396(2–3):141–149
 33. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral cannabinoid receptor, CB₂, regulates bone mass. *Proc Natl Acad Sci USA* 103(3):696–701. doi:[10.1073/pnas.0504187103](https://doi.org/10.1073/pnas.0504187103)
 34. Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, Braun J (2006) Formation of B and T cell subsets require the cannabinoid receptor CB₂. *Immunogenetics* 58(9):714–725. doi:[10.1007/s00251-006-0138-x](https://doi.org/10.1007/s00251-006-0138-x)
 35. Marchalant Y, Brownjohn PW, Bonnet A, Kleffmann T, Ashton JC (2014) Validating antibodies to the cannabinoid CB₂ receptor: antibody sensitivity is not evidence of antibody specificity. *J Histochem Cytochem* 62(6):395–404. doi:[10.1369/0022155414530995](https://doi.org/10.1369/0022155414530995)
 36. Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M (2010) Detailed characterisation of CB₂ receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. *Int J Immunopathol Pharmacol* 23(1):25–34
 37. Schmole AC, Lundt R, Gennequin B, Schrage H, Beins E, Kramer A, Zimmer T, Limmer A, Zimmer A, Otte DM (2015) Expression analysis of CB₂-GFP BAC transgenic mice. *PLoS One* 10(9):e0138986. doi:[10.1371/journal.pone.0138986](https://doi.org/10.1371/journal.pone.0138986)
 38. Petrov RR, Ferrini ME, Jaffar Z, Thompson CM, Roberts K, Diaz P (2011) Design and evaluation of a novel fluorescent CB₂ ligand as probe for receptor visualization in immune cells. *Bioorg Med Chem Lett* 21(19):5859–5862. doi:[10.1016/j.bmcl.2011.07.099](https://doi.org/10.1016/j.bmcl.2011.07.099)
 39. Fezza F, Oddi S, Di Tommaso M, De Simone C, Rapino C, Pasquariello N, Dainese E, Finazzi-Agro A, Maccarrone M (2008) Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation. *J Lipid Res* 49(6):1216–1223. doi:[10.1194/jlr.M700486-JLR200](https://doi.org/10.1194/jlr.M700486-JLR200)
 40. Galiegue S, Mary S, Marchand J, Dussosoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 232(1):54–61
 41. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, Geremia R, De Petrocellis L, Di Marzo V (2009) The endocannabinoid system and pivotal role of the CB₂ receptor in mouse spermatogenesis. *Proc Natl Acad Sci USA* 106(27):11131–11136. doi:[10.1073/pnas.0812789106](https://doi.org/10.1073/pnas.0812789106)
 42. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC (2009) Localisation and function of the endocannabinoid system in the human ovary. *PLoS One* 4(2):e4579. doi:[10.1371/journal.pone.0004579](https://doi.org/10.1371/journal.pone.0004579)
 43. Taylor AH, Abbas MS, Habiba MA, Konje JC (2010) Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. *Histochem Cell Biol* 133(5):557–565. doi:[10.1007/s00418-010-0695-9](https://doi.org/10.1007/s00418-010-0695-9)
 44. Battista N, Meccariello R, Cobellis G, Fasano S, Di Tommaso M, Pirazzi V, Konje JC, Pierantoni R, Maccarrone M (2012) The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. *Mol Cell Endocrinol* 355(1):1–14. doi:[10.1016/j.mce.2012.01.014](https://doi.org/10.1016/j.mce.2012.01.014)
 45. Meccariello R, Battista N, Bradshaw HB, Wang H (2014) Updates in reproduction coming from the endocannabinoid system. *Int J Endocrinol* 2014:412354. doi:[10.1155/2014/412354](https://doi.org/10.1155/2014/412354)
 46. Wang H, Dey SK, Maccarrone M (2006) Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. *Endocr Rev* 27(5):427–448. doi:[10.1210/er.2006-0006](https://doi.org/10.1210/er.2006-0006)
 47. Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, Marzcylo TH, Konje JC (2010) Endocannabinoids and pregnancy. *Clin Chim Acta* 411(13–14):921–930. doi:[10.1016/j.cca.2010.03.012](https://doi.org/10.1016/j.cca.2010.03.012)
 48. Rayman N, Lam KH, van der Holt B, Koss C, van Leeuwen J, Budel LM, Mulder AH, Sonneveld P, Delwel R (2011) The expression of the peripheral cannabinoid receptor CB₂ has no effect on clinical outcome in diffuse large B-cell lymphomas. *Eur J Haematol* 86(6):466–476. doi:[10.1111/j.1600-0609.2011.01596.x](https://doi.org/10.1111/j.1600-0609.2011.01596.x)
 49. Carayon P, Marchand J, Dussosoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiegue S, Mondiere P, Penarier G, Fur GL, Defrance T, Casellas P (1998) Modulation and functional involvement of CB₂ peripheral cannabinoid receptors during B-cell differentiation. *Blood* 92(10):3605–3615

50. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA (2002) Differential expression of the CB₂ cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. *Int Immunopharmacol* 2(1):69–82
51. Sherwood TA, Nong L, Agudelo M, Newton C, Widen R, Klein TW (2009) Identification of transcription start sites and preferential expression of select CB₂ transcripts in mouse and human B lymphocytes. *J Neuroimmune Pharmacol* 4(4):476–488. doi:10.1007/s11481-009-9169-z
52. Lu Q, Straiker A, Lu Q, Maguire G (2000) Expression of CB₂ cannabinoid receptor mRNA in adult rat retina. *Vis Neurosci* 17(1):91–95
53. Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001) Downregulation of cannabinoid receptor 2 (CB₂) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. *Adv Exp Med Biol* 493:223–228. doi:10.1007/0-306-47611-8_26
54. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997) Cannabinoid receptors CB₁ and CB₂: a characterization of expression and adenylate cyclase modulation within the immune system. *Toxicol Appl Pharmacol* 142(2):278–287. doi:10.1006/taap.1996.8034
55. Ashton JC, Friberg D, Darlington CL, Smith PF (2006) Expression of the cannabinoid CB₂ receptor in the rat cerebellum: an immunohistochemical study. *Neurosci Lett* 396(2):113–116. doi:10.1016/j.neulet.2005.11.038
56. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. *Eur J Biochem* 269(15):3771–3778
57. Atwood BK, Mackie K (2010) CB₂: a cannabinoid receptor with an identity crisis. *Br J Pharmacol* 160(3):467–479. doi:10.1111/j.1476-5381.2010.00729.x
58. Derbenev AV, Stuart TC, Smith BN (2004) Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. *J Physiol* 559(Pt 3):923–938. doi:10.1113/jphysiol.2004.067470
59. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB₂ receptor participation. *J Pharmacol Exp Ther* 289(3):1620–1625
60. Klegeris A, Bissonnette CJ, McGeer PL (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB₂ receptor. *Br J Pharmacol* 139(4):775–786. doi:10.1038/sj.bjp.0705304
61. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton JA, Pertwee RG (1997) Evidence for the presence of CB₂-like cannabinoid receptors on peripheral nerve terminals. *Eur J Pharmacol* 339(1):53–61
62. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB₂ receptors: immunohistochemical localization in rat brain. *Brain Res* 1071(1):10–23. doi:10.1016/j.brainres.2005.11.035
63. Suarez J, Llorente R, Romero-Zerbo SY, Mateos B, Bermudez-Silva FJ, de Fonseca FR, Viveros MP (2009) Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB₁ and CB₂ cannabinoid receptors of neonatal rats. *Hippocampus* 19(7):623–632. doi:10.1002/hipo.20537
64. Suarez J, Bermudez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, de Fonseca FR (2008) Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. *J Comp Neurol* 509(4):400–421. doi:10.1002/cne.21774
65. Stempel AV, Stumpf A, Zhang HY, Ozdogan T, Pannasch U, Theis AK, Otte DM, Wojtalla A, Racz I, Ponomarenko A, Xi ZX, Zimmer A, Schmitz D (2016) Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. *Neuron* 90(4):795–809. doi:10.1016/j.neuron.2016.03.034
66. Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Llorente-Berzal A, Viveros MP, Ishiguro H, Arinami T, Onaivi ES, Uhl GR (2009) Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB₂ isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. *Genes Brain Behav* 8(5):519–530. doi:10.1111/j.1601-183X.2009.00498.x
67. Baek JH, Darlington CL, Smith PF, Ashton JC (2013) Antibody testing for brain immunohistochemistry: brain immunolabeling for the cannabinoid CB₂ receptor. *J Neurosci Methods* 216(2):87–95. doi:10.1016/j.jneumeth.2013.03.021
68. Castaneda JT, Harui A, Kiertscher SM, Roth JD, Roth MD (2013) Differential expression of intracellular and extracellular CB₂ cannabinoid receptor protein by human peripheral blood leukocytes. *J Neuroimmune Pharmacol* 8(1):323–332. doi:10.1007/s11481-012-9430-8
69. Sanchez Lopez AJ, Roman-Vega L, Ramil Tojeiro E, Giuffrida A, Garcia-Merino A (2015) Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-beta: a longitudinal study in multiple sclerosis patients. *Clin Exp Immunol* 179(1):119–127. doi:10.1111/cei.12443
70. Agudelo M, Newton C, Widen R, Sherwood T, Nong L, Friedman H, Klein TW (2008) Cannabinoid receptor 2 (CB₂) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. *J Neuroimmune Pharmacol* 3(1):35–42. doi:10.1007/s11481-007-9088-9
71. Small-Howard AL, Shimoda LM, Adra CN, Turner H (2005) Anti-inflammatory potential of CB₁-mediated cAMP elevation in mast cells. *Biochem J* 388(Pt 2):465–473. doi:10.1042/BJ20041682
72. Chouinard F, Turcotte C, Guan X, Larose MC, Poirier S, Bouchard L, Provost V, Flamand L, Grandvaux N, Flamand N (2013) 2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against *E. coli*, *S. aureus*, HSV-1, and RSV. *J Leukoc Biol* 93(2):267–276. doi:10.1189/jlb.0412200
73. Chouinard F, Lefebvre JS, Navarro P, Bouchard L, Ferland C, Lalancette-Hebert M, Marsolais D, Laviolette M, Flamand N (2011) The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B₄ biosynthesis. *J Immunol* 186(5):3188–3196. doi:10.4049/jimmunol.1002853
74. Oka S, Ikeda S, Kishimoto S, Gokoh M, Yanagimoto S, Waku K, Sugiura T (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. *J Leukoc Biol* 76(5):1002–1009. doi:10.1189/jlb.0404252
75. Ramirez SH, Reichenbach NL, Fan S, Rom S, Merkel SF, Wang X, Ho WZ, Persidsky Y (2013) Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. *J Leukoc Biol* 93(5):801–810. doi:10.1189/jlb.1012523
76. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S (2005) Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. *Gastroenterology* 129(2):437–453. doi:10.1016/j.gastro.2005.05.026
77. Reichenbach V, Munoz-Luque J, Ros J, Casals G, Navasa M, Fernandez-Varo G, Morales-Ruiz M, Jimenez W (2013) Bacterial lipopolysaccharide inhibits CB₂ receptor expression in human monocytic cells. *Gut* 62(7):1089–1091. doi:10.1136/gutjnl-2012-303662

78. Montecucco F, Burger F, Mach F, Steffens S (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. *Am J Physiol Heart Circ Physiol* 294(3):H1145–H1155. doi:[10.1152/ajpheart.01328.2007](https://doi.org/10.1152/ajpheart.01328.2007)
79. Kurihara R, Tohyama Y, Matsusaka S, Naruse H, Kinoshita E, Tsujioka T, Katsumata Y, Yamamura H (2006) Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. *J Biol Chem* 281(18):12908–12918. doi:[10.1074/jbc.M510871200](https://doi.org/10.1074/jbc.M510871200)
80. Catani MV, Gasperi V, Catanzaro G, Baldassarri S, Bertoni A, Sinigaglia F, Avigliano L, Maccarrone M (2010) Human platelets express authentic CB(1) and CB(2) receptors. *Curr Neurovasc Res* 7(4):311–318
81. Signorello MG, Giacobbe E, Passalacqua M, Leoncini G (2013) The 2-arachidonoylglycerol effect on myosin light chain phosphorylation in human platelets. *Biochimie* 95(8):1620–1628. doi:[10.1016/j.biochi.2013.05.003](https://doi.org/10.1016/j.biochi.2013.05.003)
82. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett SM (2002) Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. *Biochem Biophys Res Commun* 290(1):91–96. doi:[10.1006/bbrc.2001.6179](https://doi.org/10.1006/bbrc.2001.6179)
83. Demuth DG, Molleman A (2006) Cannabinoid signalling. *Life Sci* 78(6):549–563. doi:[10.1016/j.lfs.2005.05.055](https://doi.org/10.1016/j.lfs.2005.05.055)
84. Chapman RS, Whetton AD, Chresta CM, Dive C (1995) Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. *Mol Pharmacol* 48(2):334–343
85. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. *FEBS Lett* 375(1–2):143–147
86. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, Calandra B, Le Fur G, Casellas P (1996) Signaling pathway associated with stimulation of CB₂ peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. *Eur J Biochem* 237(3):704–711
87. Merighi S, Gessi S, Varani K, Simioni C, Fazzi D, Mirandola P, Borea PA (2012) Cannabinoid CB₂ receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. *Br J Pharmacol* 165(6):1773–1788. doi:[10.1111/j.1476-5381.2011.01673.x](https://doi.org/10.1111/j.1476-5381.2011.01673.x)
88. Yamaori S, Ishii H, Chiba K, Yamamoto I, Watanabe K (2013) Delta-tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: involvement of cannabinoid receptor 2 and p38 MAPK. *Toxicology* 314(2–3):254–261. doi:[10.1016/j.tox.2013.10.007](https://doi.org/10.1016/j.tox.2013.10.007)
89. Kobayashi Y, Arai S, Waku K, Sugiura T (2001) Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. *J Biochem* 129(5):665–669
90. He F, Qiao ZH, Cai J, Pierce W, He DC, Song ZH (2007) Involvement of the 90-kDa heat shock protein (Hsp-90) in CB₂ cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration signaling of a G protein-coupled receptor. *Mol Pharmacol* 72(5):1289–1300. doi:[10.1124/mol.107.036566](https://doi.org/10.1124/mol.107.036566)
91. Gokoh M, Kishimoto S, Oka S, Metani Y, Sugiura T (2005) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. *FEBS Lett* 579(28):6473–6478. doi:[10.1016/j.febslet.2005.10.030](https://doi.org/10.1016/j.febslet.2005.10.030)
92. Gkoumassi E, Dekkers BG, Droge MJ, Elzinga CR, Schmidt M, Meurs H, Zaagsma J, Nelemans SA (2007) Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. *Br J Pharmacol* 151(7):1041–1048. doi:[10.1038/sj.bjp.0707320](https://doi.org/10.1038/sj.bjp.0707320)
93. Rhee MH, Nevo I, Levy R, Vogel Z (2000) Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB₂ cannabinoid receptor. *FEBS Lett* 466(2–3):300–304
94. Bari M, Spagnuolo P, Fezza F, Oddi S, Pasquariello N, Finazzi-Agro A, Maccarrone M (2006) Effect of lipid rafts on CB₂ receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. *J Immunol* 177(8):4971–4980
95. McAllister SD, Griffin G, Satin LS, Abood ME (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. *J Pharmacol Exp Ther* 291(2):618–626
96. Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A, Frenkel B, Shohami E, Bab I (2011) CB₂ cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. *J Bone Miner Res* 26(2):308–316. doi:[10.1002/jbmr.228](https://doi.org/10.1002/jbmr.228)
97. Zhou LL, Lin ZX, Fung KP, Cheng CH, Che CT, Zhao M, Wu SH, Zuo Z (2011) Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-kappaB activity. *Eur J Pharmacol* 670(2–3):399–408. doi:[10.1016/j.ejphar.2011.09.014](https://doi.org/10.1016/j.ejphar.2011.09.014)
98. Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, Goke B, Schafer C (2013) Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. *Am J Physiol Gastrointest Liver Physiol* 304(2):G181–G192. doi:[10.1152/ajpgi.00133.2012](https://doi.org/10.1152/ajpgi.00133.2012)
99. Zoratti C, Kipmen-Korgun D, Osibow K, Malli R, Graier WF (2003) Anandamide initiates Ca²⁺ signaling via CB₂ receptor linked to phospholipase C in calf pulmonary endothelial cells. *Br J Pharmacol* 140(8):1351–1362. doi:[10.1038/sj.bjp.0705529](https://doi.org/10.1038/sj.bjp.0705529)
100. Malysz J, Daza AV, Kage K, Grayson GK, Yao BB, Meyer MD, Gopalakrishnan M (2009) Characterization of human cannabinoid CB₂ receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins. *Eur J Pharmacol* 603(1–3):12–21. doi:[10.1016/j.ejphar.2008.11.047](https://doi.org/10.1016/j.ejphar.2008.11.047)
101. Larose MC, Turcotte C, Chouinard F, Ferland C, Martin C, Provost V, Laviolette M, Flamand N (2014) Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. *J Allergy Clin Immunol* 133(5):1480–1482, 1482 e1481–1483. doi:[10.1016/j.jaci.2013.12.1081](https://doi.org/10.1016/j.jaci.2013.12.1081)
102. Turcotte C, Chouinard F, Lefebvre JS, Flamand N (2015) Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. *J Leukoc Biol* 97(6):1049–1070. doi:[10.1189/jlb.3RU0115-021R](https://doi.org/10.1189/jlb.3RU0115-021R)
103. Ortega-Gutierrez S, Molina-Holgado E, Guaza C (2005) Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. *Glia* 52(2):163–168. doi:[10.1002/glia.20229](https://doi.org/10.1002/glia.20229)
104. Chiurciu V, Cencioni MT, Bisicchia E, De Bardi M, Gasperini C, Borsellino G, Centonze D, Battistini L, Maccarrone M (2013) Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. *Ann Neurol* 73(5):626–636. doi:[10.1002/ana.23875](https://doi.org/10.1002/ana.23875)
105. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in

- microglial cells. *Neuron* 49(1):67–79. doi:10.1016/j.neuron.2005.11.027
106. Correa F, Hernangomez M, Mestre L, Loria F, Spagnolo A, Docagne F, Di Marzo V, Guaza C (2010) Anandamide enhances IL-10 production in activated microglia by targeting CB₂ receptors: roles of ERK1/2, JNK, and NF-kappaB. *Glia* 58(2):135–147. doi:10.1002/glia.20907
 107. Correa F, Hernangomez-Herrero M, Mestre L, Loria F, Docagne F, Guaza C (2011) The endocannabinoid anandamide down-regulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. *Brain Behav Immun* 25(4):736–749. doi:10.1016/j.bbi.2011.01.020
 108. Malek N, Popiolek-Barczyk K, Mika J, Przewlocka B, Starowicz K (2015) Anandamide, acting via CB₂ Receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures. *Neural Plast* 2015:130639. doi:10.1155/2015/130639
 109. Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW (2007) Anandamide and Δ⁹-tetrahydrocannabinol directly inhibit cells of the immune system via CB₂ receptors. *J Neuroimmunol* 189(1–2):17–22. doi:10.1016/j.jneuroim.2007.06.001
 110. Cencioni MT, Chiurciu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB₂ receptors. *PLoS One* 5(1):e8688. doi:10.1371/journal.pone.0008688
 111. Coopman K, Smith LD, Wright KL, Ward SG (2007) Temporal variation in CB₂R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. *Int Immunopharmacol* 7(3):360–371. doi:10.1016/j.intimp.2006.11.008
 112. Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. *Cancer Immunol Immunother* 53(8):723–728. doi:10.1007/s00262-004-0509-9
 113. Rayman N, Lam KH, Laman JD, Simons PJ, Lowenberg B, Sonneveld P, Delwel R (2004) Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. *J Immunol* 172(4):2111–2117
 114. Jorda MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A, Lowenberg B, Delwel R (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. *Blood* 99(8):2786–2793
 115. Tanikawa T, Kurohane K, Imai Y (2007) Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice. *Microbiol Immunol* 51(10):1013–1019
 116. Maestroni GJ (2004) The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. *FASEB J* 18(15):1914–1916. doi:10.1096/fj.04-2190fje
 117. Kishimoto S, Oka S, Gokoh M, Sugiura T (2006) Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. *Int Arch Allergy Immunol* 140(Suppl 1):3–7. doi:10.1159/000092704
 118. Shiratsuchi A, Watanabe I, Yoshida H, Nakanishi Y (2008) Involvement of cannabinoid receptor CB₂ in dectin-1-mediated macrophage phagocytosis. *Immunol Cell Biol* 86(2):179–184. doi:10.1038/sj.icb.7100121
 119. Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, Sugiura T (2003) 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB₂ receptor-dependent mechanism. *J Biol Chem* 278(27):24469–24475. doi:10.1074/jbc.M301359200
 120. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. *J Biochem* 135(4):517–524
 121. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. *J Neurosci* 23(4):1398–1405
 122. Gokoh M, Kishimoto S, Oka S, Mori M, Waku K, Ishima Y, Sugiura T (2005) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. *Biochem J* 386(Pt 3):583–589. doi:10.1042/BJ20041163
 123. Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T (2005) Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. *J Biochem* 137(2):217–223. doi:10.1093/jb/mvi021
 124. Gasperi V, Evangelista D, Chiurciu V, Florenzano F, Savini I, Oddi S, Avigliano L, Catani MV, Maccarrone M (2014) 2-Arachidonoylglycerol modulates human endothelial cell/leukocyte interactions by controlling selectin expression through CB₁ and CB₂ receptors. *Int J Biochem Cell Biol* 51:79–88. doi:10.1016/j.biocel.2014.03.028
 125. Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, Martin BR, Peterson PK (2007) WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. *J Neuroimmune Pharmacol* 2(2):178–183. doi:10.1007/s11481-006-9040-4
 126. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes. *Glia* 49(2):211–219. doi:10.1002/glia.20108
 127. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. *J Immunol* 173(4):2373–2382
 128. Adhikary S, Kocieda VP, Yen JH, Tuma RF, Ganea D (2012) Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. *Blood* 120(18):3741–3749. doi:10.1182/blood-2012-06-435362
 129. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P (2007) CB₂-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. *Am J Physiol Heart Circ Physiol* 293(4):H2210–H2218. doi:10.1152/ajpheart.00688.2007
 130. Persidsky Y, Fan S, Dykstra H, Reichenbach NL, Rom S, Ramirez SH (2015) Activation of cannabinoid type two receptors (CB₂) diminish inflammatory responses in macrophages and brain endothelium. *J Neuroimmune Pharmacol* 10(2):302–308. doi:10.1007/s11481-015-9591-3
 131. Hao MX, Jiang LS, Fang NY, Pu J, Hu LH, Shen LH, Song W, He B (2010) The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. *J Lipid Res* 51(8):2181–2190. doi:10.1194/jlr.M001511
 132. Ross RA, Brockie HC, Pertwee RG (2000) Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. *Eur J Pharmacol* 401(2):121–130
 133. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA (2008) The cannabinoid Δ⁹-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB₂ receptor. *J Neuroimmune Pharmacol* 3(2):117–129. doi:10.1007/s11481-007-9077-z

134. Correa F, Mestre L, Docagne F, Guaza C (2005) Activation of cannabinoid CB₂ receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. *Br J Pharmacol* 145(4):441–448. doi:10.1038/sj.bjp.0706215
135. Giudice ED, Rinaldi L, Passarotto M, Facchinetti F, D'Arrigo A, Guiotto A, Carbonare MD, Battistin L, Leon A (2007) Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. *J Leukoc Biol* 81(6):1512–1522. doi:10.1189/jlb.1206738
136. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA (2009) Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. *Mol Pain* 5:25. doi:10.1186/1744-8069-5-25
137. Murकिनати S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. *FASEB J* 24(3):788–798. doi:10.1096/fj.09-141275
138. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Bertolotto M, Pelli G, Galan K, Pilet L, Kuzmanovic K, Burger F, Pane B, Spinella G, Braunerreuther V, Gayet-Ageron A, Pende A, Viviani GL, Palombo D, Dallegri F, Roux-Lombard P, Santos RA, Stergiopoulos N, Steffens S, Mach F (2012) The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. *Eur Heart J* 33(7):846–856. doi:10.1093/eurheartj/ehr449
139. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD (2002) Δ⁹-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J Neuroimmunol* 133(1–2):124–131
140. Ghosh S, Preet A, Groopman JE, Ganju RK (2006) Cannabinoid receptor CB₂ modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. *Mol Immunol* 43(14):2169–2179. doi:10.1016/j.molimm.2006.01.005
141. Robinson RH, Meissler JJ, Fan X, Yu D, Adler MW, Eisenstein TK (2015) A CB₂-selective cannabinoid suppresses T-cell activities and increases tregs and IL-10. *J Neuroimmune Pharmacol* 10(2):318–332. doi:10.1007/s11481-015-9611-3
142. Csoka B, Nemeth ZH, Mukhopadhyay P, Spolarics Z, Rajesh M, Federici S, Deitch EA, Batkai S, Pacher P, Hasko G (2009) CB₂ cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. *PLoS One* 4(7):e6409. doi:10.1371/journal.pone.0006409
143. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tuting T, Zimmer A (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. *Science* 316(5830):1494–1497. doi:10.1126/science.1142265
144. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. *Mol Pharmacol* 74(1):20–33. doi:10.1124/mol.108.047035
145. Engel MA, Kellermann CA, Burnat G, Hahn EG, Rau T, Konturek PC (2010) Mice lacking cannabinoid CB₁-, CB₂-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. *J Physiol Pharmacol* 61(1):89–97
146. Duerr GD, Heinemann JC, Gestrich C, Heuft T, Klaas T, Keppel K, Roell W, Klein A, Zimmer A, Velten M, Kilic A, Bindila L, Lutz B, Dewald O (2015) Impaired border zone formation and adverse remodeling after reperfused myocardial infarction in cannabinoid CB₂ receptor deficient mice. *Life Sci* 138:8–17. doi:10.1016/j.lfs.2014.11.005
147. Amenta PS, Jallo JI, Tuma RF, Hooper DC, Elliott MB (2014) Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. *J Neuroinflammation* 11:191. doi:10.1186/s12974-014-0191-6
148. Zhao Y, Liu Y, Zhang W, Xue J, Wu YZ, Xu W, Liang X, Chen T, Kishimoto C, Yuan Z (2010) WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. *Eur J Pharmacol* 649(1–3):285–292. doi:10.1016/j.ejphar.2010.09.027
149. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. *Nature* 434(7034):782–786. doi:10.1038/nature03389
150. McCallip RJ, Nagarkatti M, Nagarkatti PS (2005) Δ⁹-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J Immunol* 174(6):3281–3289
151. Zarruk JG, Fernandez-Lopez D, Garcia-Yebenes I, Garcia-Gutierrez MS, Vivancos J, Nombela F, Torres M, Burguete MC, Manzanares J, Lizasoain I, Moro MA (2012) Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. *Stroke* 43(1):211–219. doi:10.1161/STROKEAHA.111.631044
152. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB₁ on neurons and CB₂ on autoreactive T cells. *Nat Med* 13(4):492–497. doi:10.1038/nm1561
153. Batkai S, Mukhopadhyay P, Horvath B, Rajesh M, Gao RY, Mahadevan A, Amere M, Battista N, Lichtman AH, Gauson LA, Maccarrone M, Pertwee RG, Pacher P (2012) Δ⁸-Tetrahydrocannabinol prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB₂ receptors. *Br J Pharmacol* 165(8):2450–2461. doi:10.1111/j.1476-5381.2011.01410.x
154. Tang J, Chen Q, Guo J, Yang L, Tao Y, Li L, Miao H, Feng H, Chen Z, Zhu G (2015) Minocycline attenuates neonatal germinal-matrix-hemorrhage-induced neuroinflammation and brain edema by activating cannabinoid receptor 2. *Mol Neurobiol*. doi:10.1007/s12035-015-9154-x
155. Newton CA, Chou PJ, Perkins I, Klein TW (2009) CB₁ and CB₂ cannabinoid receptors mediate different aspects of Δ⁹-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by *Legionella pneumophila* infection. *J Neuroimmune Pharmacol* 4(1):92–102. doi:10.1007/s11481-008-9126-2
156. Buchweitz JP, Karmaus PW, Williams KJ, Harkema JR, Kaminski NE (2008) Targeted deletion of cannabinoid receptors CB₁ and CB₂ produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Δ⁹-tetrahydrocannabinol. *J Leukoc Biol* 83(3):785–796. doi:10.1189/jlb.0907618
157. Di Filippo C, Rossi F, Rossi S, D'Amico M (2004) Cannabinoid CB₂ receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. *J Leukoc Biol* 75(3):453–459. doi:10.1189/jlb.0703303
158. Giannini L, Nistri S, Mastroianni R, Cinci L, Vannacci A, Mariottini C, Passani MB, Mannaioni PF, Bani D, Masini E (2008) Activation of cannabinoid receptors prevents antigen-

- induced asthma-like reaction in guinea pigs. *J Cell Mol Med* 12(6A):2381–2394. doi:[10.1111/j.1582-4934.2008.00258.x](https://doi.org/10.1111/j.1582-4934.2008.00258.x)
159. Tambaro S, Casu MA, Mastinu A, Lazzari P (2014) Evaluation of selective cannabinoid CB₁ and CB₂ receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. *Eur J Pharmacol* 729:67–74. doi:[10.1016/j.ejphar.2014.02.013](https://doi.org/10.1016/j.ejphar.2014.02.013)
 160. Sardinha J, Kelly ME, Zhou J, Lehmann C (2014) Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. *Mediators Inflamm* 2014:978678. doi:[10.1155/2014/978678](https://doi.org/10.1155/2014/978678)
 161. Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D, Tuma RF (2011) Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. *J Neurotrauma* 28(12):2417–2427. doi:[10.1089/neu.2011.1853](https://doi.org/10.1089/neu.2011.1853)
 162. Zoppi S, Madrigal JL, Caso JR, Garcia-Gutierrez MS, Manzanares J, Leza JC, Garcia-Bueno B (2014) Regulatory role of the cannabinoid CB₂ receptor in stress-induced neuroinflammation in mice. *Br J Pharmacol* 171(11):2814–2826. doi:[10.1111/bph.12607](https://doi.org/10.1111/bph.12607)
 163. Amenta PS, Jallo JI, Tuma RF, Elliott MB (2012) A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. *J Neurosci Res* 90(12):2293–2305. doi:[10.1002/jnr.23114](https://doi.org/10.1002/jnr.23114)
 164. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci USA* 99(16):10819–10824. doi:[10.1073/pnas.152334899](https://doi.org/10.1073/pnas.152334899)
 165. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998) Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. *FEBS Lett* 422(1):69–73
 166. Rouzer CA, Marnett LJ (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. *Chem Rev* 111(10):5899–5921. doi:[10.1021/cr2002799](https://doi.org/10.1021/cr2002799)
 167. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B (2007) The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. *Br J Pharmacol* 152(5):787–794. doi:[10.1038/sj.bjp.0707425](https://doi.org/10.1038/sj.bjp.0707425)
 168. Wen J, Ribeiro R, Tanaka M, Zhang Y (2015) Activation of CB₂ receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. *Neuropharmacology* 99:196–209. doi:[10.1016/j.neuropharm.2015.07.010](https://doi.org/10.1016/j.neuropharm.2015.07.010)
 169. Costola-de-Souza C, Ribeiro A, Ferraz-de-Paula V, Calefi AS, Aloia TP, Gimenes-Junior JA, de Almeida VI, Pinheiro ML, Palermo-Neto J (2013) Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. *PLoS One* 8(10):e77706. doi:[10.1371/journal.pone.0077706](https://doi.org/10.1371/journal.pone.0077706)
 170. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. *J Pharmacol Exp Ther* 334(1):182–190. doi:[10.1124/jpet.109.164806](https://doi.org/10.1124/jpet.109.164806)
 171. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF, Lichtman AH (2012) The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. *Br J Pharmacol* 165(8):2485–2496. doi:[10.1111/j.1476-5381.2011.01445.x](https://doi.org/10.1111/j.1476-5381.2011.01445.x)
 172. Krustev E, Reid A, McDougall JJ (2014) Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints. *Arthritis Res Ther* 16(5):437. doi:[10.1186/s13075-014-0437-9](https://doi.org/10.1186/s13075-014-0437-9)
 173. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG (2011) Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. *FASEB J* 25(8):2711–2721. doi:[10.1096/fj.10-176602](https://doi.org/10.1096/fj.10-176602)
 174. Galanakis DK (1992) Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications. *Semin Thromb Hemost* 18(1):44–52. doi:[10.1055/s-2007-1002409](https://doi.org/10.1055/s-2007-1002409)
 175. Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, Nasui M, Sugiura T (2006) Involvement of the cannabinoid CB₂ receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. *J Immunol* 177(12):8796–8805
 176. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) Modulation of the cannabinoid CB₂ receptor in microglial cells in response to inflammatory stimuli. *J Neurochem* 95(2):437–445. doi:[10.1111/j.1471-4159.2005.03380.x](https://doi.org/10.1111/j.1471-4159.2005.03380.x)
 177. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P (2006) COX-2, CB₂ and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. *BMC Neurol* 6:12. doi:[10.1186/1471-2377-6-12](https://doi.org/10.1186/1471-2377-6-12)
 178. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005) Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. *Neuroscience* 132(4):1093–1102. doi:[10.1016/j.neuroscience.2005.02.010](https://doi.org/10.1016/j.neuroscience.2005.02.010)
 179. Oka S, Yanagimoto S, Ikeda S, Gokoh M, Kishimoto S, Waku K, Ishima Y, Sugiura T (2005) Evidence for the involvement of the cannabinoid CB₂ receptor and its endogenous ligand 2-arachidonoylglycerol in 12-*O*-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. *J Biol Chem* 280(18):18488–18497. doi:[10.1074/jbc.M413260200](https://doi.org/10.1074/jbc.M413260200)
 180. Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. *N Engl J Med* 322(18):1277–1289. doi:[10.1056/NEJM199005033221805](https://doi.org/10.1056/NEJM199005033221805)
 181. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther* 10(2):R43. doi:[10.1186/ar2401](https://doi.org/10.1186/ar2401)
 182. Gui H, Liu X, Wang ZW, He DY, Su DF, Dai SM (2014) Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. *Rheumatology (Oxford)* 53(5):802–809. doi:[10.1093/rheumatology/ket447](https://doi.org/10.1093/rheumatology/ket447)
 183. Fukuda S, Kohsaka H, Takayasu A, Yokoyama W, Miyabe C, Miyabe Y, Harigai M, Miyasaka N, Nanki T (2014) Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. *BMC Musculoskelet Disord* 15:275. doi:[10.1186/1471-2474-15-275](https://doi.org/10.1186/1471-2474-15-275)
 184. Sophocleous A, Landao-Bassonga E, Van't Hof RJ, Idris AI, Ralston SH (2011) The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. *Endocrinology* 152(6):2141–2149. doi:[10.1210/en.2010-0930](https://doi.org/10.1210/en.2010-0930)
 185. Gui H, Liu X, Liu LR, Su DF, Dai SM (2015) Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis. *Immunobiology* 220(6):817–822. doi:[10.1016/j.imbio.2014.12.012](https://doi.org/10.1016/j.imbio.2014.12.012)
 186. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. *Arthritis Rheum* 50(3):985–998. doi:[10.1002/art.20050](https://doi.org/10.1002/art.20050)

187. Insull W Jr (2009) The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. *Am J Med* 122(1 Suppl):S3–S14. doi:[10.1016/j.amjmed.2008.10.013](https://doi.org/10.1016/j.amjmed.2008.10.013)
188. Chiurchiu V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M (2014) Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. *Atherosclerosis* 233(1):55–63. doi:[10.1016/j.atherosclerosis.2013.12.042](https://doi.org/10.1016/j.atherosclerosis.2013.12.042)
189. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, Liu W, Zhang W, Shen Y, Xu W, Liang X, Chen T (2010) Activation of cannabinoid CB₂ receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. *J Cardiovasc Pharmacol* 55(3):292–298. doi:[10.1097/FJC.0b013e3181d2644d](https://doi.org/10.1097/FJC.0b013e3181d2644d)
190. Netherland CD, Pickle TG, Bales A, Thewke DP (2010) Cannabinoid receptor type 2 (CB₂) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. *Atherosclerosis* 213(1):102–108. doi:[10.1016/j.atherosclerosis.2010.07.060](https://doi.org/10.1016/j.atherosclerosis.2010.07.060)
191. Delsing DJ, Leijten FP, Arts K, van Eenennaam H, Garritsen A, Gijbels MJ, de Winther MP, van Elsas A (2011) Cannabinoid receptor 2 deficiency in haematopoietic cells aggravates early atherosclerosis in LDL receptor deficient mice. *Open Cardiovasc Med J* 5:15–21. doi:[10.2174/1874192401105010015](https://doi.org/10.2174/1874192401105010015)
192. Netherland-Van Dyke C, Rodgers W, Fulmer M, Lahr Z, Thewke D (2015) Cannabinoid receptor type 2 (CB₂) dependent and independent effects of WIN55,212-2 on atherosclerosis in Ldlr-null mice. *J Cardiol Ther* 3(2):53–63. doi:[10.12970/2311-052X.2015.03.02.2](https://doi.org/10.12970/2311-052X.2015.03.02.2)
193. Willecke F, Zeschky K, Ortiz Rodriguez A, Colberg C, Auwarter V, Kneisel S, Hutter M, Lozhkin A, Hoppe N, Wolf D, von zur Muhlen C, Moser M, Hilgendorf I, Bode C, Zirlik A (2011) Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. *PLoS One* 6(4):e19405. doi:[10.1371/journal.pone.0019405](https://doi.org/10.1371/journal.pone.0019405)
194. Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm Bowel Dis* 12(Suppl 1):S3–S9
195. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B (2004) The endogenous cannabinoid system protects against colonic inflammation. *J Clin Invest* 113(8):1202–1209. doi:[10.1172/JCI19465](https://doi.org/10.1172/JCI19465)
196. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, Sibaev A, Massa F, Buckley NE, Lutz B, Goke B, Brand S, Patel KD, Sharkey KA (2008) Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB₁ and CB₂ receptors. *J Mol Med (Berl)* 86(8):925–936. doi:[10.1007/s00109-008-0359-6](https://doi.org/10.1007/s00109-008-0359-6)
197. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA (2009) Activation of the cannabinoid 2 receptor (CB₂) protects against experimental colitis. *Inflamm Bowel Dis* 15(11):1678–1685. doi:[10.1002/ibd.20960](https://doi.org/10.1002/ibd.20960)
198. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. *Biochem Pharmacol* 85(9):1306–1316. doi:[10.1016/j.bcp.2013.01.017](https://doi.org/10.1016/j.bcp.2013.01.017)
199. Bento AF, Marcon R, Dutra RC, Claudino RF, Cola M, Leite DF, Calixto JB (2011) β -caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB₂ receptor activation and PPAR γ pathway. *Am J Pathol* 178(3):1153–1166. doi:[10.1016/j.ajpath.2010.11.052](https://doi.org/10.1016/j.ajpath.2010.11.052)
200. El Bakali J, Gilleron P, Body-Malapel M, Mansouri R, Muccioli GG, Djouina M, Barczyk A, Klupsch F, Andrzejak V, Lipka E, Furman C, Lambert DM, Chavatte P, Desreumaux P, Millet R (2012) 4-Oxo-1,4-Dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis. *J Med Chem* 55(20):8948–8952. doi:[10.1021/jm3008568](https://doi.org/10.1021/jm3008568)
201. Tourteau A, Andrzejak V, Body-Malapel M, Lemaire L, Lemoine A, Mansouri R, Djouina M, Renault N, El Bakali J, Desreumaux P, Muccioli GG, Lambert DM, Chavatte P, Rigo B, Leleu-Chavain N, Millet R (2013) 3-Carboxamido-5-aryl-isoxazoles as new CB₂ agonists for the treatment of colitis. *Bioorg Med Chem* 21(17):5383–5394. doi:[10.1016/j.bmc.2013.06.010](https://doi.org/10.1016/j.bmc.2013.06.010)
202. El Bakali J, Muccioli GG, Body-Malapel M, Djouina M, Klupsch F, Ghinet A, Barczyk A, Renault N, Chavatte P, Desreumaux P, Lambert DM, Millet R (2015) Conformational restriction leading to a selective CB₂ cannabinoid receptor agonist orally active against colitis. *ACS Med Chem Lett* 6(2):198–203. doi:[10.1021/ml500439x](https://doi.org/10.1021/ml500439x)
203. Giblin GM, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatheron AJ, Slingsby BP, Rawlings DA, Goldsmith P, Brown AJ, Haslam CP, Clayton NM, Wilson AW, Chessell IP, Whittington AR, Green R (2007) Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB₂ receptor agonist for the treatment of inflammatory pain. *J Med Chem* 50(11):2597–2600. doi:[10.1021/jm061195+](https://doi.org/10.1021/jm061195+)
204. Mitchell WL, Giblin GM, Naylor A, Eatheron AJ, Slingsby BP, Rawlings AD, Jandu KS, Haslam CP, Brown AJ, Goldsmith P, Clayton NM, Wilson AW, Chessell IP, Green RH, Whittington AR, Wall ID (2009) Pyridine-3-carboxamides as novel CB₂ agonists for analgesia. *Bioorg Med Chem Lett* 19(1):259–263. doi:[10.1016/j.bmcl.2008.10.118](https://doi.org/10.1016/j.bmcl.2008.10.118)
205. Giblin GM, Billinton A, Briggs M, Brown AJ, Chessell IP, Clayton NM, Eatheron AJ, Goldsmith P, Haslam C, Johnson MR, Mitchell WL, Naylor A, Perboni A, Slingsby BP, Wilson AW (2009) Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB₂ agonist for the treatment of chronic pain. *J Med Chem* 52(19):5785–5788. doi:[10.1021/jm9009857](https://doi.org/10.1021/jm9009857)